Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Granisetron · Kytril, Sancuso

Small molecule · Antagonist of 5-hydroxytryptamine 3 (5-HT3) receptor (HTR3A) · developed by Roche

Approved FDA, Dec 1993
2 Registered trials

What is Granisetron?

Granisetron is a selective 5-HT3 receptor antagonist that blocks serotonin binding at peripheral vagal nerve terminals and central chemoreceptor trigger zone receptors, preventing chemotherapy-induced vomiting signals. A controlled-release formulation encapsulates granisetron in a biodegradable poly(ortho ester) polymer for sustained release. It is studied in chemotherapy-induced nausea and vomiting.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Kytril, Sancuso, Sustol, SUSTOL, APF-530, BRL 43694
Drug type
Small molecule
Targets
5-hydroxytryptamine 3 (5-HT3) receptor (HTR3A)
Mechanism
Antagonist of 5-hydroxytryptamine 3 (5-HT3) receptor (HTR3A)
Pathways
serotonin signaling, vagal afferent stimulation
Therapy area
Gastroenterology, Oncology
Developer
Roche
In trials of
HRTX
FDA status
Approved as Kytril, Sancuso, Sustol (December 29, 1993), NDA020239 · FDA label
UNII
WZG3J2MCOL

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05434663 Phase 4 Chemotherapy-Induced Nausea and Vomiting (CINV) Active not recruiting HRTX
NCT02106494 Phase 3 Chemotherapy-induced Nausea and Vomiting Completed HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chemotherapy-Induced Nausea and Vomiting (CINV)Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.